Miraculins Updates Market on Regulatory Progress in China for its Scout DS(R) Diabetes Screening Device
Company's Preparations for CFDA Product Testing Submission Now Complete
WINNIPEG, MANITOBA--(May 22, 2015) - Miraculins Inc. (TSX VENTURE:MOM) ("Miraculins" or the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces that it has now completed all required preparations for the submission of its Scout DS® device for product testing in compliance with Chinese Food and Drug Administration (CFDA) requirements. Product testing, which must precede clinical trials in China, relates to a series of safety and operational tests that the CFDA testing center and its engineers decide are suitable for a medical device including electrical testing, biocompatibility testing, mechanical testing, stability testing, integrity testing, and other related tests to verify the device's specified operating parameters.
- Category: Diagnostic / Testing
- Published: 22 May 2015
- Written by Editor